Definium Therapeutics, Inc. (DFTX) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-167.95M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.47× | Operating cash flow / net income. Period ending 2026-06-30. $-167.95M ÷ $-353.79M ≈ 0.47× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -167.95M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -353.79M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-167.95M | (m) | (m) | (m) | (m) | $-353.79M | (m) | (m) | (m) | 0.47× |
| 2026-03-31 | (m) | (m) | $-144.77M | (m) | (m) | (m) | (m) | $-237.54M | (m) | (m) | (m) | 0.61× |
| 2025-12-31 | (m) | (m) | $-131.56M | (m) | (m) | (m) | (m) | $-183.79M | (m) | (m) | (m) | 0.72× |
| 2025-09-30 | (m) | (m) | $-113.94M | (m) | (m) | (m) | (m) | $-168.10M | (m) | (m) | (m) | 0.68× |
| 2025-06-30 | (m) | (m) | $-101.56M | (m) | (m) | (m) | (m) | $-114.52M | (m) | (m) | (m) | 0.89× |
| 2025-03-31 | (m) | (m) | $-91.95M | (m) | (m) | (m) | (m) | $-77.63M | (m) | (m) | (m) | 1.18× |
| 2024-12-31 | (m) | (m) | $-79.13M | (m) | (m) | (m) | (m) | $-108.68M | (m) | (m) | (m) | 0.73× |
| 2024-09-30 | (m) | (m) | $-74.34M | (m) | (m) | (m) | (m) | $-97.80M | (m) | (m) | (m) | 0.76× |
| 2024-06-30 | (m) | (m) | $-73.78M | (m) | (m) | (m) | (m) | $-102.04M | (m) | (m) | (m) | 0.72× |
| 2024-03-31 | (m) | (m) | $-67.63M | (m) | (m) | (m) | (m) | $-125.32M | (m) | (m) | (m) | 0.54× |
| 2023-12-31 | (m) | (m) | $-64.36M | (m) | (m) | (m) | (m) | $-95.73M | (m) | (m) | (m) | 0.67× |
| 2023-09-30 | (m) | (m) | $-56.65M | (m) | (m) | (m) | (m) | $-76.77M | (m) | (m) | (m) | 0.74× |
| 2023-06-30 | (m) | (m) | $-49.32M | (m) | (m) | (m) | (m) | $-75.33M | (m) | (m) | (m) | 0.65× |
| 2023-03-31 | (m) | (m) | $-50.60M | (m) | (m) | (m) | (m) | $-63.16M | (m) | (m) | (m) | 0.80× |
| 2022-12-31 | (m) | (m) | $-50.14M | (m) | (m) | (m) | (m) | $-56.80M | (m) | (m) | (m) | 0.88× |
| 2022-09-30 | (m) | (m) | $-45.12M | (m) | (m) | (m) | (m) | $-68.72M | (m) | (m) | (m) | 0.66× |
| 2022-06-30 | (m) | (m) | $-52.61M | (m) | (m) | (m) | (m) | $-69.43M | (m) | (m) | (m) | 0.76× |
| 2022-03-31 | (m) | (m) | $-48.65M | (m) | (m) | (m) | (m) | $-97.73M | (m) | (m) | (m) | 0.50× |
| 2021-12-31 | (m) | (m) | $-45.82M | (m) | (m) | (m) | (m) | $-93.04M | (m) | (m) | (m) | 0.49× |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $-23.60M | (m) | (m) | (m) | (m) | $-33.94M | (m) | (m) | (m) | 0.70× |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cronos Group Inc. (CRON) | $1.223B | ||
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B |